Baird has reduced its price target for Agilent Technologies (A) to $155, reflecting a revised assessment of the company’s near-term revenue and margin trajectory. The move follows a broader reassessment of demand in the life sciences and industrial markets.
- Baird reduced Agilent Technologies (A) price target to $155
- 2025 revenue: ~$5.2 billion, with 4.5% YoY growth in core instrumentation
- Revised 2026 revenue growth forecast: 3.8%, down from 5.0%
- Q2 2025 product order decline: 2% sequentially
- Gross margins expected to remain above 70% in 2026
- Impact on XLK and XLF sectors remains limited due to diversification
Baird has revised its price target for Agilent Technologies, Inc. (A) down to $155 from a previous level, citing cautious expectations for fiscal 2026 and 2027. The adjustment comes amid softer-than-anticipated demand in key end markets, including pharmaceutical development and environmental testing, which are critical to Agilent’s revenue base. The firm maintains a neutral rating on the stock, suggesting no immediate change in conviction but a more conservative view on near-term earnings potential. Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, reports 2025 revenue of approximately $5.2 billion, with a 4.5% year-over-year growth in its core instrumentation segment. However, Baird notes that second-half 2025 demand decelerated, with capital spending delays from academic and government labs contributing to a 2% sequential decline in product orders. This has led to a downward revision in expected annual revenue growth from 5.0% to 3.8% for fiscal 2026. The price target cut is part of a broader sector review within the technology and healthcare technology space, with the S&P 500 Health Care Sector (XLK) and Financials Sector (XLF) both showing moderate volatility over the past month. While Agilent remains a core holding in several healthcare technology indices, the revised outlook may influence portfolio positioning among growth-focused funds. Market participants are monitoring the company’s upcoming Q1 earnings release for further clarity on inventory levels and customer order trends. Analysts are particularly attentive to Agilent’s ability to maintain gross margins above 70% amid pricing pressures and supply chain adjustments.